PLS3基因新发大片段缺失导致罕见X连锁早发性骨质疏松及对唑来膦酸的反应
在一名中国非近亲结婚家庭的男孩中,通过靶向二代测序和Sanger测序鉴定出PLS3基因从内含子9到3'UTR的12,229 bp大片段缺失(E10-E16del),该缺失可能由Alu重复序列和断点连接处26 bp微同源介导。唑来膦酸治疗可显著提高骨密度Z评分并重塑压缩椎体。
要点
- PLS3基因E10-E16del大片段缺失是X连锁早发性骨质疏松的新致病突变。
- 该缺失可能由Alu重复序列和断点处26 bp微同源介导。
- 唑来膦酸治疗可显著提高骨密度Z评分并重塑压缩椎体。
核心结论
- 首次鉴定PLS3基因大片段缺失突变,阐明了该缺失的可能机制,该突变导致X连锁早发性骨质疏松和多发椎体骨折,丰富了该罕见疾病的病因谱。
研究设计与样本
- 对一名来自中国非近亲结婚家庭的X连锁早发性骨质疏松男孩进行靶向二代测序和Sanger测序验证,并观察唑来膦酸对骨折频率和骨密度的影响。
主要发现
- 低骨密度和多发椎体压缩骨折是X连锁早发性骨质疏松的主要表型。
- 鉴定出PLS3基因12,229 bp缺失,涉及内含子9至3'UTR(E10-E16del)。
- 该大片段缺失可能由Alu重复序列和每个断点连接处26 bp的微同源介导。
- 唑来膦酸治疗可显著提高骨密度Z评分并重塑压缩的椎体。
关键数值与推荐
- PLS3基因缺失为12,229 bp,涉及内含子9至3'UTR(E10-E16del)。
- 断点连接处微同源长度为26 bp。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: We identified a novel large fragment deletion from intron 9 to 3'UTR in PLS3 (E10-E16del) in one Chinese boy with X-linked early-onset osteoporosis and vertebral fractures, which expanded the pathogenic spectrum of X-linked early-onset osteoporosis. Treatment with zoledronic acid was beneficial for increasing BMD and reshaping the vertebral bodies of this patient. INTRODUCTION: X-linked early-onset osteoporosis is a rare disease, which is characterized by low bone mineral density (BMD), vertebral compression fractures (VCFs), and/or long bone fractures. We aimed to detect the phenotype and the underlying pathogenic mutation of X-linked early-onset osteoporosis in a boy from a nonconsanguineous Chinese family. METHODS: We investigated the pathogenic mutation of the patient with X-linked early-onset osteoporosis by targeted next-generation sequencing and confirmed it by Sanger sequencing. We also observed the effects of zoledronic acid on fracture frequency and BMD of the patient. RESULTS: Low BMD and multiple VCFs were the main phenotypes of X-linked early-onset osteoporosis. We identified a total of 12,229 bp deletion in PLS3, involving intron 9 to the 3'UTR (E10-E16 del). This large fragment deletion might be mediated by Alu repeats and microhomology of 26 bp at each breakpoint junction. Zoledronic acid treatment could significantly increase the Z-score of BMD and reshape the compressed vertebral bodies. CONCLUSION: We identified a large fragment deletion mutation in PLS3 for the first time and elucidated the possible mechanism of the deletion, which led to X-linked early-onset osteoporosis and multiple vertebral fractures. Our findings would enrich the etiology spectrum of this rare disease.
引用
- Lv F, Ma M, Liu W, et al. A novel large fragment deletion in PLS3 causes rare X-linked early-onset osteoporosis and response to zoledronic acid. Osteoporos Int. 2017. PMID: 28620780. doi:10.1007/s00198-017-4094-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。